ReviewThe Journal of adolescent health : official publication of the Society for Adolescent Medicine2012
Age-specific human papillomavirus antibody and deoxyribonucleic acid prevalence: a global review.
Review in The Journal of adolescent health : official publication of the Society for Adolescent Medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years.Human vaccines & immunotherapeutics · 2014Trial
- The Role of HPV in the Development of Cutaneous Squamous Cell Carcinoma-Friend or Foe?Cancers · 2025Review
- Disease Progression of WHIM Syndrome in an International Cohort of 66 Pediatric and Adult Patients.Journal of clinical immunology · 2022Article
- Effects of the age of vaccination on the humoral responses to a human papillomavirus vaccine.NPJ vaccines · 2022Article
- Seroprevalence of mucosal and cutaneous human papillomavirus (HPV) types among children and adolescents in the general population in Germany.BMC infectious diseases · 2022Article
- How Enhancing Immunity to Low-Risk HPV Could Cure Recurrent Respiratory Papillomatosis.The Laryngoscope · 2021Review
- Seroprevalence of HPV serotypes 6, 11, 16 and 18 in unvaccinated children from Mexico City.Epidemiology and infection · 2019Article
- Paediatric Virology and its interaction between basic science and clinical practice (Review).International journal of molecular medicine · 2018Review
- High-risk human papillomavirus seroprevalence in men and women of six different ethnicities in Amsterdam, the Netherlands: The HELIUS study.Papillomavirus research (Amsterdam, Netherlands) · 2017Article
- Recent advances in understanding and preventing human papillomavirus-related disease.F1000Research · 2017Review
- Observational
- Seroprevalence of cutaneous human papillomaviruses (HPVs) among men in the multinational HPV Infection in Men study.The Journal of general virology · 2016Article
- Human papillomavirus DNA positivity and seropositivity in rural Chinese men and women: a population-based cross-sectional study.Scientific reports · 2016Article
- Human papillomavirus prevalence in South African women and men according to age and human immunodeficiency virus status.BMC infectious diseases · 2015Article
- Human papillomavirus 16/18 seroprevalence in unvaccinated women over 30 years with normal cytology and with high grade cervical abnormalities in Australia: results from an observational study.BMC infectious diseases · 2014Observational
- Oral human papillomavirus infection and head and neck cancers in HIV-infected individuals.Current opinion in oncology · 2013Review
- Seroprevalence of human papillomavirus (HPV) type 6 and 16 vary by anatomic site of HPV infection in men.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2012Article
- An exploration of the natural and acquired immunological mechanisms to high-risk human papillomavirus infection and unmasking immune escape in cervical cancer: A concise synopsis.Tzu chi medical journalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeGlobal data on human papillomavirus (HPV) serological and deoxyribonucleic acid (DNA) prevalence are essential to optimize HPV prophylactic vaccination strategies.
methodsWe conducted a global review of age-specific HPV antibody and studies with both antibody and DNA prevalence for HPV-16, -18, -6, and -11.
resultsOne hundred seventeen studies were included; participants' ages ranged from several hours to >90 years. HPV-16 seroprevalence was generally higher in Africa, Central and South America, and North America, more prevalent among women than among men, and peaked around ages 25-40 years. HPV-18 seroprevalence was generally lower than HPV-16 with a later age peak. Data were limited for HPV-6 and -11, both of which peaked at ages similar to HPV-18. Among 9-26-year-old females, HPV-16 seroprevalence ranged from 0%-31% in North America, 21%-30% in Africa, 0%-23% in Asia/Australia, 0%-33% in Europe, and 13%-43% in Central and South America. HPV-16/-18 DNA prevalence peaked 10-15 years before corresponding HPV-16/-18 antibody prevalence.
conclusionsFemales within the HPV vaccine-eligible age-group (9-26 years) had a range of dual HPV-16 DNA and serology negativity from 81%-87%, whereas 90%-98% were HPV-16 DNA negative. Serology and DNA data are lacking worldwide for females younger than age 15 years, the prime target group for vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.